Medpace Holdings Analyst Price Targets

Wall Street analyst price targets and consensus rating for Medpace Holdings (MEDP).

Price Target Range — 13 Quarters

Analyst Consensus — 14 Analysts

4Buy

10Hold

Consensus RatingHold# Analysts14Avg. Consensus PT$534Upside to Avg. PT-11.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 7, 2026	Mizuho	Ann Hynes	PT Raise	Outperform	$665→$700
Oct 7, 2026	Barclays	Luke Sergott	PT Raise	Equal-Weight	$600→$625
Sep 30, 2026	UBS	Kevin Caliendo	Upgrade	Sell→Neutral	$405→$673
Jul 24, 2026	Mizuho	Ann Hynes	PT Raise	Outperform	$586→$665
Jul 24, 2026	BMO Capital	Sean Dodge	PT Raise	Market Perform	$400→$600
Jul 24, 2026	Truist Securities	Jailendra Singh	PT Raise	Hold	$462→$609
Jul 24, 2026	TD Cowen	Charles Rhyee	PT Raise	Hold	$419→$492
Jul 24, 2026	RBC Capital	Ryan Halsted	PT Raise	Outperform	$484→$692
Jul 24, 2026	Baird	Eric Coldwell	PT Raise	Neutral	$547→$624
Jul 13, 2026	Mizuho	Ann Hynes	PT Raise	Outperform	$495→$586
Jul 8, 2026	Baird	Eric Coldwell	Downgrade	Outperform→Neutral	$477→$547
Jul 7, 2026	Jefferies	David Windley	Downgrade	Buy→Hold	$490→$515
Apr 24, 2026	Barclays	Luke Sergott	PT Cut	Equal-Weight	$500→$450
Apr 24, 2026	BMO Capital	Sean Dodge	PT Cut	Market Perform	$460→$400
Apr 24, 2026	RBC Capital	Ryan Halsted	PT Cut	Outperform	$522→$484
Apr 24, 2026	Baird	Eric Coldwell	PT Cut	Outperform	$565→$477
Mar 6, 2026	Barclays	Luke Sergott	Upgrade	Underweight→Equal-Weight	$500
Mar 3, 2026	RBC Capital	Ryan Halsted	Initiate	Outperform	$522
Feb 18, 2026	TD Cowen	Charles Rhyee	Upgrade	Sell→Hold	$462→$419
Feb 13, 2026	Jefferies	David Windley	Upgrade	Hold→Buy	$560

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Mizuho Maintains Outperform on Medpace Holdings, Raises Price Target to $700

Mizuho analyst Ann Hynes maintains Medpace Holdings (NASDAQ:MEDP) with a Outperform and raises the price target from $665 to $700.

Benzinga Newsdesk

PRO
Barclays Maintains Equal-Weight on Medpace Holdings, Raises Price Target to $625

Barclays analyst Luke Sergott maintains Medpace Holdings (NASDAQ:MEDP) with a Equal-Weight and raises the price target from $600 to $625.

Benzinga Newsdesk

PRO
UBS Upgrades Medpace Holdings to Neutral, Raises Price Target to $673

UBS analyst Kevin Caliendo upgrades Medpace Holdings (NASDAQ:MEDP) from Sell to Neutral and raises the price target from $405 to $673.

Benzinga Newsdesk

PRO
Mizuho Maintains Outperform on Medpace Holdings, Raises Price Target to $665

Mizuho analyst Ann Hynes maintains Medpace Holdings (NASDAQ:MEDP) with a Outperform and raises the price target from $586 to $665.

Benzinga Newsdesk

PRO
BMO Capital Maintains Market Perform on Medpace Holdings, Raises Price Target to $600

BMO Capital analyst Sean Dodge maintains Medpace Holdings (NASDAQ:MEDP) with a Market Perform and raises the price target from $400 to $600.

Benzinga Newsdesk

PRO
Truist Securities Maintains Hold on Medpace Holdings, Raises Price Target to $609

Truist Securities analyst Jailendra Singh maintains Medpace Holdings (NASDAQ:MEDP) with a Hold and raises the price target from $462 to $609.

Benzinga Newsdesk

Medpace Holdings Inc

Medpace Holdings Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Mizuho Maintains Outperform on Medpace Holdings, Raises Price Target to $700

PRO
Barclays Maintains Equal-Weight on Medpace Holdings, Raises Price Target to $625

PRO
UBS Upgrades Medpace Holdings to Neutral, Raises Price Target to $673

PRO
Mizuho Maintains Outperform on Medpace Holdings, Raises Price Target to $665

PRO
BMO Capital Maintains Market Perform on Medpace Holdings, Raises Price Target to $600

PRO
Truist Securities Maintains Hold on Medpace Holdings, Raises Price Target to $609

People Also Watch

People Also Watch

Medpace Holdings Inc

Medpace Holdings Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROMizuho Maintains Outperform on Medpace Holdings, Raises Price Target to $700

PROBarclays Maintains Equal-Weight on Medpace Holdings, Raises Price Target to $625

PROUBS Upgrades Medpace Holdings to Neutral, Raises Price Target to $673

PROMizuho Maintains Outperform on Medpace Holdings, Raises Price Target to $665

PROBMO Capital Maintains Market Perform on Medpace Holdings, Raises Price Target to $600

PROTruist Securities Maintains Hold on Medpace Holdings, Raises Price Target to $609

People Also Watch

People Also Watch

PRO
Mizuho Maintains Outperform on Medpace Holdings, Raises Price Target to $700

PRO
Barclays Maintains Equal-Weight on Medpace Holdings, Raises Price Target to $625

PRO
UBS Upgrades Medpace Holdings to Neutral, Raises Price Target to $673

PRO
Mizuho Maintains Outperform on Medpace Holdings, Raises Price Target to $665

PRO
BMO Capital Maintains Market Perform on Medpace Holdings, Raises Price Target to $600

PRO
Truist Securities Maintains Hold on Medpace Holdings, Raises Price Target to $609